Teriflunomide

Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS 3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 11 Jun 2021
Managing pediatric MS in the current era 1:46
Managing pediatric MS in the current era
Tanuja Chitnis • 26 Apr 2021
Is long-term teriflunomide treatment safe in MS? 2:13
Is long-term teriflunomide treatment safe in MS?
Mark Freedman • 3 Mar 2021
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS 2:12
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS
Tanuja Chitnis • 24 May 2020
The content of VJNeurology is intended for healthcare professionals